Allergic diseases, including asthma, allergic rhinitis (hay fever), atopic dermatitis (eczema), food allergy, and anaphylaxis, are major health concerns with increasing prevalence particularly in the "developed" world. These diseases affect a large proportion of the population, result in considerable morbidity, and are, in some circumstances, life-threatening. Asthma affects about 300 million people worldwide and kills several thousand people each year in the United States alone. Anaphylaxis is frequently lifethreatening, although the use of adrenaline/ epinephrine auto-injectors has improved this situation in some countries. It has long been known that being atopic (allergic) and having one allergic disease increases the likelihood of developing other allergic diseases during a person's lifetime-the so-called atopic march. Allergic diseases are driven by an in appropriate immune response to normally innocuous antigens such as cat dander, peanuts, grass pollen, or house dust mites. Despite intensive research, we still do not fully understand why some individuals develop antigen-specific pathogenic immune responses to these allergens. Almost as mysterious are the T cells that drive the allergic response. In this issue, Wambre et al. bring us a step closer to identifying and understanding the enigmatic T cells underpinning allergy (1) . They show that a new subset of pathogenic T H 2 cells (T H 2A) is found specifically in patients with allergic disease and link depletion of T H 2A cells with allergen desensitization immunotherapy.
T H 2 CELLS IN ALLERGIC DISEASE
A number of elegant studies in both mouse and human have shown that the pathology of allergic disease is driven by the type 2 cytokines, which induce different hallmarks of allergic disease. The type 2 cytokine IL-4 induces B cell isotype switching to produce IgE; IL-5 promotes eosinophil differentiation, migration, and survival; and IL-13 induces mucus hypersecretion and fibrosis. Type 2 cytokines can be produced by a variety of innate immune cell types, including mast cells, basophils, and the more recently identified group 2 innate lymphoid cells (ILC2s). However, antigen-specific expression of type 2 cytokines in response to allergen is restricted to the T H 2 subset of T helper cells.
The T H 2 cytokines are not constitutively expressed by T H 2 cells but are transiently activated and secreted upon antigen stimulation, making it challenging to identify the T H 2 cell subset in the absence of a specific allergen. In humans, T H 2 cells can be identified by expression of the prostaglandin D 2 receptor CRT H 2 (also known as DP2 or CD294). Paradoxically, however, numerous studies have failed to detect an increased prevalence of CRT H 2 + T H 2 cells in patients with allergic disease. Recent studies have suggested that there is functional heterogeneity within the T H 2 cell subset, with some memory T H 2 cell populations being able to express high levels of IL-5 ( 2, 3), IL-17 (4), or IFN- (5) alongside IL-4 and IL-13, giving rise to the concept of a pathogenic effector T H 2 (peT H 2 or Tpath2) cell subset (6) . The nature of this T H 2 cell subset and the methods used to identify it are an area of active research, with several potential phenotypic markers being proposed in both mouse and human studies. These markers include the receptors for the epithelial-derived cytokines IL-25 (IL17RB) (7), IL-33 (ST2) (8) , and thymic stromal lymphopoietin (TSLP receptor; TSLPR) (9). These epithelial-derived cytokines are believed to be released from damaged epithelium in response to viral infection, allergen exposure, or physical damage and potently induce type 2 cytokine production from a variety of cell types, including ILC2s, basophils, mast cells, and T H 2 cells.
IDENTIFICATION OF PATHOGENIC T H 2 CELLS
In their new study, Wambre et al. (1) identified allergen-specific T cells in patients by selecting patients with allergy to alder tree pollen, using peptides from alder tree allergens in combination with fluorescently labeled major histocompatibility class II (MHCII) tetramers. This is how an allergen-specific T cell would normally "see" an allergen on the surface of an antigen-presenting cell and therefore allowed the investigators to accurately identify the T cells responsible for the response to a particular allergen. They used this approach to screen a large panel of cell surface molecules in an attempt to identify markers that are selectively expressed on allergen-specific T helper cells. As expected, they found that most allergenspecific T cells were CRT H + phenotype were present in greater numbers, whereas they were absent in nonallergic people, suggesting that these cells may be causing allergic disease.
Although identifying allergen-specific T H 2 cells that may cause disease is a big step forward, the authors' approach requires prior knowledge of the allergen involved and the ability to develop specific peptide MHCII tetramers against the allergen. From a clinical viewpoint, this may not always be possible and would thus restrict the usefulness of this approach. However, Wambre and colleagues went on to see whether they could identify this T H 2 cell population in patients without using the MHCII tetramer technology. They found that, compared with nonallergic people, allergic individuals had higher frequencies of these pathogenic T H (Fig. 1) . To attempt to demonstrate that the pathogenic T H 2 cells were the cells that respond to allergen in atopic individuals, the researchers examined patients undergoing two different allergen challenge situations: natural exposure of hay fever sufferers during the pollen season and a double-blind, placebocontrolled peanut challenge in patients with peanut allergy. In both situations, the pathogenic T H 2 cell subset (CD27 − CRT H 2 + CD161 + ) was activated in response to in vivo allergen challenge, as assessed by expression of the activation marker CD38, in contrast to the conventional T H 2 cell population (CRT H 2 + CD161 − ). Thus, the authors appear to have identified the allergen-responsive pathogenic T H 2 cell population in humans and report that it is a subset of the total T H 2 cell pool.
Allergen desensitization immunotherapy is a mainstay of treatment for several allergic diseases, including allergic rhinitis and bee venom anaphylaxis, although the precise mechanisms of action are not fully understood. Patients are administered either subcutaneously or sublingually increasing amounts of allergen to desensitize them. Wambre et al. went on to examine the impact of a peanut immunotherapy treatment on their pathogenic T H 2 cell subset (1). Remarkably, they found that the pathogenic T H 2 cell population was selectively deleted in patients undergoing the active immunotherapy treatment and that this specifically correlated with clinical benefit, suggesting that pathogenic T H 2 cells are a clinically relevant target cell population in allergic disease.
MECHANISTIC INSIGHTS
To explore the mechanisms by which pathogenic T H 2 cells might cause disease, the investigators performed multiparametric intracellular cytokine staining and demonstrated that pathogenic T H 2 cells express more IL-5 and IL-9 than do conventional T H 2 cells and do not express IL-17 or IFN-. Transcriptome profiling of the pathogenic T H 2 cells identified an interesting set of genes up-regulated in this population, including the IL-25 receptor (IL17RB), IL-33 receptor (ST2; IL1RL1) and TSLPR (CRLF2), Cox-2 (PTGS2), and hematopoietic prostaglandin D synthase (HPGDS). Collectively, this gene expression profile appears very similar to those of the various pathogenic effector T H 2 cell populations identified by several other groups. We have previously identified IL17RB + ST2 + T H 2 cells in nasal polyposis (7), and others have found HPGDS + pathogenic effector T H 2 cells in patients with eosinophilic gastrointestinal disease and atopic dermatitis (9). Wambre et al. failed to detect surface expression of IL17RB or ST2 in their experiments, possibly due to the use of different antibodies for immunostaining (1). It is highly likely that all of these studies have been examining the same or very similar pathogenic effector T H 2 cell subsets, which provides hope that therapies targeting this cell population will provide benefit in a wide variety of allergic diseases.
One outstanding question regarding pathogenic T H 2 cells surrounds the mechanism of differentiation compared to conventional T H 2 cells. Classical T H 2 and pathogenic T H 2 cells express GATA3, the master regulator of T H 2 differentiation. It will be important to determine whether additional transcription factors are involved in directing the pathogenic T H 2 transcriptional program; one candidate for this could be the nuclear receptor PPAR, reported to be up-regulated in pathogenic T H 2 cells by Wambre et al. (1) . It will also be important to understand the role of the epithelial-derived cytokines in regulating pathogenic T H 2 cell function and activation. ) and epithelial cytokine receptors (IL17RB, ST2, and TSLPR). Pathogenic effector T H 2 cells are activated by allergen and produce type 2 cytokines such as IL-4, IL-5, IL-9, and IL-13. These cells can also secrete prostaglandin D 2 (PGD 2 ) in response to epithelial cytokines due to their expression of PTGS2 and HPGDS. CRT H 2 antagonists and antibodies targeting epithelial cytokines may block pathogenic effector T H 2 cell recruitment or activation, thus ameliorating the allergic response. These pathogenic effector T H 2 cells that drive allergen-specific immune responses may be a useful therapeutic target for treating allergic disease.
CLINICAL IMPLICATIONS
because several pharmaceutical companies have developed new therapeutics targeting IL-25, IL-33, TSLP, and their respective receptors (IL17RB, ST2, and TSLPR), and these therapeutics are now entering clinical testing. Furthermore, given that pathogenic T H 2 cells express both the biosynthetic pathway for PGD 2 production (Cox-2 and HPGDS) and a receptor for PGD 2 (CRT H 2), it will be critical to examine the effect of blockade of this pathway in allergic disease. The recent study of the drug fevipiprant in asthma, a small-molecule antagonist of CRT H 2, suggests that CRT H 2 antagonism may be one mechanism worth exploring for treatment of other allergic diseases (10) . The study by Wambre et al. implicates a new pathogenic T H 2 cell subset in allergic disease and reveals a panel of cell surface markers that the research community now can use to examine the importance of these pathogenic T H 2 cells in clinical trials of new therapeutic agents.
